Premium
Bioengineered skeletal muscle for defect replacement in a rodent model
Author(s) -
Machingal Masood Ahammed,
Corona Benjamin T,
Kesireddy Venu,
Andersson Kristian,
Herco Maja,
Vishwjit Sonia,
Bishwokarma Bimjhana,
Zhao Weixin,
Yoo James J,
Christ George J
Publication year - 2010
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.24.1_supplement.824.3
Subject(s) - skeletal muscle , isometric exercise , in vivo , medicine , muscle tissue , chemistry , anatomy , biology , microbiology and biotechnology
Loss of functional skeletal muscle due to congenital and acquired conditions, such as traumatic injury, tumor excision, etc., produces a physiological deficit for which there is still no effective clinical treatment. The goal of these studies is to develop clinically relevant tissue engineered skeletal muscle (TESKM) that can eventually be used for functional restoration of injured muscle in vivo. TESKM constructs developed by seeding rat muscle precursor cells on porcine bladder acellular matrix were preconditioned in a bioreactor for one week and implanted in nude mice (for 1–2 months) to repair a defect created by excising 50% of the native Latissimus Dorsi muscle (LD). Isometric tetanic specific force (ITSF) generated by the un‐repaired defect only group (49.2± 1.8 mN/mm2) was significantly lower (p<0.01) than that of native LD (161.1± 22.4 mN/mm2). ITSF of TESKM constructs increased over time from one month (20.06± 6.4 mN/mm2) to two month (86.75± 45.7 mN/mm2) which is 53% of native LD. Besides this, the TESKM constructs recorded higher tension than the unrepaired group (12.6± 4.1 g) both at 1 month (16.88± 7.1 g) and 2 month (22.34± 5.6 g, p<0.05), with the latter being 73% of native LD (30.67± 4.4g). Taken together, these initial observations indicate that TESKM can generate approximately half the ITSF of native LD after two months of implantation, illustrating the potential clinical utility of this approach. Grant Funding Source : AFIRM